MedTrace Logo

Persistence of Antibody Response to N. Meningitidis Group C in Children

NCT00316654 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 489

Last updated 2017-07-25

No results posted yet for this study

Summary

Persistence of Antibody Response to N. meningitidis Group C in Children

Conditions

  • Prevention of Meningococcal Infection

Interventions

BIOLOGICAL

Meningococcal C conjugate vaccine

Sponsors & Collaborators

Principal Investigators

  • Novartis Vaccines Drug Information Services · Novartis Vaccines & Diagnostics

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00316654 on ClinicalTrials.gov